Cure Genetics website screenshot

Cure Genetics

Cure Genetics (克睿基因) is a clinical-stage biotechnology company founded in 2016 and based in Suzhou, Jiangsu, China, developing cell and gene therapies for solid tumors and genetic diseases. Its differentiated pipeline is built on two proprietary platforms: AIMS CAR-NKT, a cell-therapy approach engineered to improve solid-tumor infiltration and modulate the tumor microenvironment, and VELP, an AAV (adeno-associated viral) vector technology targeting the nervous system, heart, and kidneys. Lead programs include CGC729, an anti-CD70 CAR-NKT therapy in Phase I trials for renal cell carcinoma, and CGC-602, a PD-1-IL-2v bispecific molecule for cancer immunotherapy. The company is backed by Qiming Venture Partners, Advantech Capital, and Oriza Holdings. It publishes no public API, developer platform, or technical documentation; this profile is maintained in the API Evangelist network as a company record surfaced from the Qiming portfolio.

Cure Genetics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Gene Therapy, Cell Therapy, and Oncology.

Cure Genetics’ developer surface includes engineering blog, support, and 2 more developer resources.

🌐 Visit website 📡 Source on GitHub
8.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyGene TherapyCell TherapyOncologyGenetic DiseaseLife SciencesChina

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 8.8/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 1.3 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/curegenetics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Curegenetics Domain Security

TLSv1.3 · HSTS

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Company 2

The organization behind the API

Website
Website
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: curegenetics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/curegenetics.png
name: Cure Genetics
description: 'Cure Genetics (克睿基因) is a clinical-stage biotechnology company founded in 2016 and based in Suzhou, Jiangsu,
  China, developing cell and gene therapies for solid tumors and genetic diseases. Its differentiated pipeline is built on
  two proprietary platforms: AIMS CAR-NKT, a cell-therapy approach engineered to improve solid-tumor infiltration and modulate
  the tumor microenvironment, and VELP, an AAV (adeno-associated viral) vector technology targeting the nervous system, heart,
  and kidneys. Lead programs include CGC729, an anti-CD70 CAR-NKT therapy in Phase I trials for renal cell carcinoma, and
  CGC-602, a PD-1-IL-2v bispecific molecule for cancer immunotherapy. The company is backed by Qiming Venture Partners, Advantech
  Capital, and Oriza Holdings. It publishes no public API, developer platform, or technical documentation; this profile is
  maintained in the API Evangelist network as a company record surfaced from the Qiming portfolio.'
url: https://raw.githubusercontent.com/api-evangelist/curegenetics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- qiming
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biotechnology
- Gene Therapy
- Cell Therapy
- Oncology
- Genetic Disease
- Life Sciences
- China
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/curegenetics-domain-security.yml
- type: Website
  url: https://curegenetics.com
- type: Blog
  url: https://curegenetics.com/gsxw.html
- type: Support
  url: https://curegenetics.com/lianxifangshi.html
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence